Is Spectrum Pharma’s FDA Update Good News for Breast Cancer Patients?
Spectrum Pharma shares dipped on Thursday after the firm announced a key update from the FDA on its treatment of neutropenia in breast cancer patients.
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares dipped on Thursday after the firm announced a key update from the U.S. Food and Drug Administration (FDA).
Specifically, the firm announced that it had submitted a Biologics License Application (BLA) with the FDA for Rolontis (eflapegrastim). The submission is based on results from two large, positive pivotal trials.
The BLA for Rolontis is supported by data from two identically designed Phase 3 clinical trials, Advance and Recover, which evaluated the safety and efficacy of Rolontis in 643 early-stage breast cancer patients for the treatment of neutropenia due to myelosuppressive cytoxic chemotherapy.
The study Advance was conducted under a special protocol assessment with the FDA. In both studies, Rolontis demonstrated the pre-specified hypothesis of non-inferiority in duration of severe neutropenia (DSN) and a similar safety profile to pegfilgrastim. Rolontis also demonstrated non-inferiority to pegfilgrastim in the DSN across all four cycles in both studies.
Joe Turgeon, president and CEO of Spectrum, commented:
Rolontis is an important and significant future growth driver for our company. Today’s milestone brings us one step closer to bringing the first novel G-CSF to healthcare providers in over 15 years in a large market that is familiar to Spectrum.
Shares of Spectrum Pharma were last seen down about 11% at $8.47, in a 52-week range of $6.22 to $25.29. The consensus analyst price target is $28.50.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
